Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076959 | 0.92 | BDKRB1 (0.40) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL530308 | 0.91 | NR1D1 (0.40) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL526306 | 0.87 | ALDH1A1 (0.42) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL526223 | 0.82 | TDP1 (0.40) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL5640330 | 0.78 | KMT2A (0.45) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL526531 | 0.76 | NR1D1 (0.38) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL10076958 | 0.76 | TDP1 (0.36) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL525996 | 0.75 | KMT2A (0.51) | ALDH1A1MEN1KMT2ALMNAF2 | |
| SCHEMBL20089218 | 0.74 | NR1D1 (0.51) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL530309 | 0.74 | NR1D1 (0.37) | MAPTALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| EP-2598507-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | MAPT 3684/4885ALDH1A1 339/4885MEN1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.